Business Wire06.08.16
STENTYS, a company commercializing a self-apposing coronary stent, has received CE Marking for the longest version of its Xposition S Sirolimus-eluting self-apposing stent.
The Xposition stent portfolio already included three lengths (17 millimeters, 22 millimeters and 27 millimeters), and this 37 millimeter drug-eluting stent (DES) is particularly well-suited to the treatment of lesions in the left main coronary artery and in tapered vessels, according to the company. Segments longer than 25 millimeters have been demonstrated to have a higher degree of tapering (diameter difference of 0.5 millimeters or more) and to be an independent predictor of acute stent malapposition with conventional stents1. Cardiologists now only need to implant a single self-apposing stent rather than a long conventional stent, thus minimizing the risk of malapposition and related complications.
“We are very pleased to be able to offer cardiologists this new Self-Apposing drug- eluting stent that is expected to increase our market share in the hospitals where we market our products,” said Gonzague Issenmann, CEO and co-founder of STENTYS.
STENTYS develops and commercializes solutions to treat complex artery disease. STENTYS’ Self-Apposing drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one-year mortality rate and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS’ commercial network in Europe, the Middle East, Asia and Latin America.
The Xposition stent portfolio already included three lengths (17 millimeters, 22 millimeters and 27 millimeters), and this 37 millimeter drug-eluting stent (DES) is particularly well-suited to the treatment of lesions in the left main coronary artery and in tapered vessels, according to the company. Segments longer than 25 millimeters have been demonstrated to have a higher degree of tapering (diameter difference of 0.5 millimeters or more) and to be an independent predictor of acute stent malapposition with conventional stents1. Cardiologists now only need to implant a single self-apposing stent rather than a long conventional stent, thus minimizing the risk of malapposition and related complications.
“We are very pleased to be able to offer cardiologists this new Self-Apposing drug- eluting stent that is expected to increase our market share in the hospitals where we market our products,” said Gonzague Issenmann, CEO and co-founder of STENTYS.
STENTYS develops and commercializes solutions to treat complex artery disease. STENTYS’ Self-Apposing drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one-year mortality rate and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS’ commercial network in Europe, the Middle East, Asia and Latin America.